Li et al. found that PLCG2 could be an effective biomarker for predicting the prognosis and immune status of the tumor microenvironment in patients with soft-tissue sarcoma (STS), which provided important insights into understanding the role of PLCG2 in immune remodeling of the tumor microenvironment 8. Here, PLCG2 is linked to telomere syndrome.